Ranking of treatments based on NMA results. (A,C) Distribution of the probabilities of being at each rank, together with mean rank. Cumulative ranking probabilities for each treatment evaluated in term of (B) PFS and (D) OS. (E) All of the SUCRA values for each regimen in regard to PFS, OS, ORR, CR, and toxicity (TOX; in this case, the higher the SUCRA, the safer the regimen is for patients). An average SUCRA and the average ranking are provided. BEV, bevacizumab; DAR, daratumumab; DEX, dexamethasone; ELO, elotuzumab; IXA, ixazomib; PAN, panobinostat; PLD, pegylated liposomal doxorubicin; SILT, siltuximab; VOR, vorinostat.